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Abstract
Postmenopausal endometriosis is a rare clinical condition. The diagnosis and treatment of an endometriotic lesion
in postmenopausal women is complicated. First line treatment choice should be surgical, given that there is a
potential risk of malignancy. Medical treatment may be considered as second line or as an alternate first line
treatment whenever surgery is contradicted and aims to alter the hormonal pathway leading to endometriosis
progress. Different hormonal regimens have been administered to these patients, with conflicting however results.
Aromatase inhibitors (AIs) represent one of the most recently used drugs for postmenopausal endometriosis.
Clinical data for the use of (AIs) in postmenopausal patients is scarce. Up to date only 5 case reports are available
regarding the use of these agents in postmenopausal women. Although definite conclusions may be premature,
AIs appear to considerably improve patients’ symptoms and reduce endometriotic lesions size. Nonetheless the
subsequent induced reduction in estrogen production, leads to certain short-term and long-term adverse effects.
Despite the limited available data, AIs appear to represent a new promising method which may improve
symptoms and treat these patients, either as first line treatment, when surgery is contraindicated or as a second
line for recurrences following surgical treatment. However, careful monitoring of patients’ risk profile and further
research regarding long-term effects and side-effects of these agents is essential prior implementing them in
everyday clinical practice.
Review
Endometriosis is a clinical condition mainly seen among
women of reproductive age. Nonetheless, it may also affect
post-menopausal women [1], with a prevalence varying
from 2 to 5% [2]. In 1942 Haydon reported a 78-years-old
patient with endometriosis, [3], whereas in another study
138 endometriosis patients were reported to be 2 or more
years post-menopausal [4]. Aromatase inhibitors (AIs)
represent one of the most recently used drugs for postme-
nopausal endometriosis. They were first used for the treat-
ment of postmenopausal, estrogen receptor positive
advanced breast cancer due to their ability to reduce estro-
gen production through inhibition of cytochrome P450.
Pathogenesis of postmenopausal endometriosis
Endometriosis is always estrogen dependent. While in
premenopausal women the ovaries are the main source
of estrogen production, in postmenopausal patients
estrogens are derived either from exogenous administra-
tion, or from endogenous extraovarian production. Sev-
eral reports have linked postmenopausal endometriosis
with hormone therapy [5,6]. However, estrogen produc-
tion during menopause may be derived from extra-ovar-
ian sources such as the adrenal glands, the skin, the
endometrial stroma, and the adipose tissue [7], with the
latter probably accounting the larger part of estrogen
production through aromatation of adrenal gland andro-
gen [8].
Treatment options for patients with postmenopausal
endometriosis
First line treatment for endometriosis in postmenopau-
sal patients should be surgical. The rationale behind
such an approach is that any postmenopausal mass has
a potential risk of malignancy and therefore should be
removed [9]. On the other hand, the risk of malignant
transformation of endometriosis may be increased[10].
However, despite the fact that surgical approach should
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are increased [11,12]and therefore an effective second
line treatment for these patients is mandatory. Further-
more, given that operation may not always be feasible,
an alternative first line treatment should be considered.
Medical treatment aims to alter the hormonal pathway
leading to endometriosis progress. The use of GnRH
agonists, progestins or danazol, intend through a step-
wise pathway to decrease estrogen production, or alter
the estrogenic effect. Yet, considering that treatment
with either GnRH agonists [7]or progestins appears be
ineffective in postmenopausal patients [11], the need for
alternative drugs to reduce estrogen production is
mandatory.
AIs may be considered an efficient treatment modality
for these patients since, compared to other hormonal
therapies such as GnRH agonists, they have the ability
to further block extraovarian estrogen production which
is the main estrogen source for these women.
Aromatase inhibitors (AIs)
Aromatase Inhibitors were first used for the treatment
of postmenopausal, estrogen receptor positive advanced
breast cancer [13]. Their ability to reduce estrogen pro-
duction is through inhibition of cytochrome P450, a key
enzyme that catalyzes conversion of andostenendione
and testosterone to estrone and estradiol[14].
Letrozole and anastrozole are triazole derivatives that
are reversible, competitive AIs and, at doses of 1-5 mg/
day, inhibit estrogen levels by 97% to more than 99%
[15], whereas exemestane is a steroidal, irreversible inhi-
bitor that binds to the active site of the aromatase
enzyme and inactivates it effectively at a dose of 25 mg/
day. AIs may offer a new alternative for postmenopausal
patients with endometriosis through the alteration of
mechanisms involved in molecular development of
endometriosis [16].
Evidence regarding the use of AIs in premenopausal
patients is far more extensive compared to postmeno-
pausal women, mainly due to the considerable difference
in the prevalence of disease among these groups of
patients. Nonetheless, it appears that AIs in premeno-
pausal endometriosis, represent only a part of the thera-
peutic plan. Previous reports have raised arguments
regarding the proposed beneficial effect of AIs in these
women, suggesting that this may be attributed to the
combined use with other agents (e.g. GnRH agonists,
danazol, oral contraceptives (OCs), progestins) [17]. The
main reason for these objections is the fact that in pre-
menopausal women the main source of estrogens is the
ovary. Consequently, premenopausal endometriosis is
often successfully suppressed by estrogen deprivation
with GnRH analogs or the induction of surgical meno-
pause [18]. Therefore, in there women AIs may only be
justified when GnRH analogs fail to control the disease
through the elimination of estradiol secreted by the
ovary [18], probably due to the presence of significant
estradiol production that continues in the adipose tissue,
skin, and endometriotic implant per se during the
GnRH agonist treatment.
On the contrary, in postmenopausal women the only
estrogen activity is related to the production from extra-
ovarian sources and consequently AIs appear to be
effective in treating severe endometriosis through block-
ade of extraovarian estrogen production. This is the key
for the efficacy of AIs in the management of hormone
receptor positive breast cancer. At the moment 3
rd gen-
eration of AIs are used for the treatment of postmeno-
pausal breast cancer patients [18]. Hence, given that
they successfully control breast cancer disease in post-
menopausal women though the reduction in circulating
estrogens [13], it is likely that they may also have effect
in postmenopausal endometriosis. Blockage of aroma-
tase activity derived from extraovarian sites with an aro-
matase inhibitor may keep a larger number of patients
in remission for longer periods of time. Furthermore,
the effect of AIs in postmenopausal endometriosis may
even be greater given that they are involved in the
pathologic pathway within the endometriotic lesions. An
intracrine mechanism production of large quantities of
estrogen has been proposed within the ectopic tissue
endometriotic cells. Endometriotic implants although
histologically similar to eutopic endometrium, appear to
be different in their molecular base and this may give
rise to extreme production and impaired metabolism of
estradiol [8,11,18,19]. Therefore, AIs can theoretically
markedly reduce this production and thus decrease the
size of the lesions.
Available evidence regarding the use of AIs for the
treatment of postmenopausal endometriosis
Although a prospective randomized trial showed that
AIs in combination with GnRH analogues increased the
pain-free interval and decreased symptoms recurrence
rates following surgery in premenopausal patients with
severe endometriosis [20], clinical data for the use of
(AIs) in postmenopausal patients is limited.
Up to date only 5 case reports are available regarding
the use of AIs in postmenopausal women and thus defi-
nite conclusions may be premature (table 1). Patients’
age ranged from 47 to 61 years old. The majority of
them had total abdominal hysterectomy and bilateral
oophorectomy at earlier age. Two patients had received
hormonal replacement therapy during menopause, one
until recurrence of endometriosis [11]and one more
than 3 years prior recurrence[7]. The majority of
women had been previously treated for endometriosis
with either surgery, or GnRH agonists or progestins.
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Page 3 of 5Finally, all cases involved patients with either surgical
[7,11,21,22] or natural [23]menopause.
AIs and symptoms relief in postmenopausal patients
In all treated patients, administration of letrozole or
anastrozole appeared to improve pain related to endo-
metriosis, either when treatment was administered for 4
months or for up to 15 months. Furthermore, letrozole
appeared to improve all the other symptoms, such as
urinary tract and bowel symptoms, whenever these sys-
tems were affected by endometriosis. Nonetheless, exe-
mestane did not improve endometriosis symptoms in
one patient; when in the same patient letrozole was sub-
sequently administered, a significant beneficial effect on
symptoms relief was observed. Although one may inter-
pret this observation as a potential difference between
these two agents’ efficacy, this should be interpreted
with caution, given the short term of administration of
exemestane [21].
Besides subjective improvement, related to patients’
reported symptoms, letrozole or anastrozole has shown
a beneficial effect in quantitative parameters such as the
endometriotic lesions size. In all of the patients in
which clinical manifestation of the disease was the pre-
sence of endometriotic masses, AIs significantly reduced
t h es i z eo ft h el e s i o n sa sm e a s u r e db yi m a g i n g
techniques.
The only symptom that appeared not to improve even
15 months after the administration of anastrozole was
ureteral endometriosis. However this patient suffered
from extensive ureteral fibrosis. Thus, a potential expla-
n a t i o nf o rt h i sl a c ko fe f f e c to ft r e a t m e n tm a yb et h e
inability of these agents to improve ureteral obstruction,
since fibrosis does not respond to hormonal therapy
[24,25].
Side effects of AIs-how can they be minimized in patients
with endometriosis
Despite the fact that AIs appear to considerably improve
patients’ symptoms and reduce endometriotic lesions
size, their use and the subsequent induced reduction in
estrogen production, leads to certain short-term and
long-term adverse effects. Hot flushes, vaginal dryness,
arthralgias, decreased bone mineral density, have been
reported [26]. However, the most important risk asso-
ciated with AIs administration is osteoporosis and an
increased fracture rate [26]. Long term use of AIs in the
adjuvant setting has been associated with a significantly
higher bone fracture rate compared to tamoxifen espe-
cially in patients with advanced age, smoking history,
osteoporosis at baseline, previous bone fracture, and
previous hormonal replacement therapy[27].
Among the patients treated up to date with AIs for post-
menopausal endometriosis, only one reported hot flushes
after 4 months of letrozole administration, as side-effect
of medication; co-administration of micronized estradiol
0,5 mg daily improved hot flushes and no pain recurrence
occurred over the following 4 months.
To reduce the risk of osteoporosis in high-risk
patients, bisphosphonates may be co-administered with
AIs during long-term treatment. For breast cancer
patients the American Society of Clinical Oncologists
recommends that bone mineral density screening should
be repeated annually in all patients receiving aromatase
inhibitor adjuvant therapy, and bisphosphonate therapy
should be initiated when the Bone Mineral Density
Measurement which is commonly reported in terms of
T-score, are -2.5 or lower [28]. Among the available stu-
dies, co-administration of biphosphonates (aledronate)
was given in two patients; still one of them reported
letrozole associated bone loss with bone mineral density
marginally reduced following 9 months treatment with 1
mg anastrozole.
Conclusions
Postmenopausal endometriosis is a rare clinical condi-
tion which may significantly impair patients’ quality of
life. Despite the considerably limited available data, AIs
may be a new promising method which could poten-
tially improve symptoms and treat these patients, either
as first line treatment, when surgery is contraindicated
or as a second line for recurrences following surgical
treatment. The crucial however question remains
whether such an approach has the potential to be an
effective long term treatment, given that current reports
involve few patients with a limited follow-up. Further-
more another serious issue is whether AIs truly is a
cost-benefit method. Taking into account that treatment
with AIs may significantly impair bone mineral density
and increase the rate of bone fractures, it is intriguing
to clarify whether the benefits gained from this treat-
ment modality outnumber the harms in patients with
postmenopausal endometriosis. Furthermore, prior
administrating these agents in patients with postmeno-
pausal endometriosis considering patient’s risk profile
may be the most stepwise approach.
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